Global News Wire: Pluristem Therapeutics Forms Strategic Alliance with ChaBio & Diostech

testingPluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech. Furthermore, they filed their first Investigational New Drug Application (IND) for their product known as Pluristem’s PLacental eXpanded cells with the Korean Food and Drug Administration.

The PLX will be used for the treatment of intermittent claudication as well as peripheral arterial diseases (PAD). Their approach parallels the protocol used by Pluritsem in their USA trials. With the alliance with Cha, Pluristem will have access to a lot more capital as well as resources to conduct more trials in Korea and to fulfill unmet medical needs on a more global basis. Market Cap: 180.02 million; Volume: 600; 12 Month Trail: $2.45-$5.00.

View the full article here: (

View the profile page here: (

The comments are closed.